Skip to main content
Vivesto logo

Vivesto — Investor Relations & Filings

Ticker · VIVE ISIN · SE0000722365 LEI · 5493003TZPR4B7QO9L49 ST Manufacturing
Open in API
Filings indexed 1,069 across all filing types
Latest filing 2018-09-18 Legal Proceedings Report
Country SE Sweden
Listing ST VIVE

About Vivesto

https://www.vivesto.com/en/

Vivesto is a specialty pharmaceutical company focused on drug development in oncology. The company aims to provide new therapeutic options for patients suffering from hard-to-treat cancers where significant medical needs exist. Its research and development efforts are centered on creating innovative treatments and enhancing the intravenous delivery of established and novel drugs. The company's lead product is Apealea, a formulation of the cancer drug paclitaxel.

Recent filings

Filing Released Lang Actions
Update regarding the Market Authorization Application of Apealea in the European Union
Legal Proceedings Report Classification · 99% confidence The document is a short press release (1780 characters) dated September 18, 2018, providing an update on a Market Authorization Application (Apealea) with the European Medicines Agency (EMA). It is not a full financial report (like 10-K or IR), nor is it a standard earnings release (ER) or management discussion (MDA). It concerns a specific regulatory/legal update regarding product approval status. Since it is a specific announcement that doesn't fit the defined categories like LTR (Legal Proceedings Report) or ER, and it is a direct communication about a regulatory process update, the most appropriate general category is Regulatory Filings (RNS), which serves as the fallback for miscellaneous regulatory announcements not covered elsewhere.
2018-09-18 English
Uppdatering beträffande Apealeas marknadsansökan hos EMA
Regulatory Filings Classification · 98% confidence The document is a short press release ("PRESSMEDDELANDE") dated September 18, 2018, providing an update regarding a regulatory application process with the European Medicines Agency (EMA) concerning a scientific committee meeting (CHMP). It explicitly states that no oral explanation is required. The text concludes with a statement that this information is required to be made public under the EU Market Abuse Regulation, indicating it is a mandatory regulatory disclosure that doesn't fit the specific financial report categories (10-K, IR, ER, etc.). Since it is a general regulatory announcement that doesn't fit other specific categories like Director's Dealing (DIRS), Dividend (DIV), or Capital Change (CAP), the most appropriate fallback category is Regulatory Filings (RNS). The document length is short (1711 chars), but it is the primary disclosure itself, not an announcement *about* another report, so RPA is less suitable than RNS for this type of regulatory news update.
2018-09-18 Swedish
Oasmia completes a private placement of new convertible instruments in the amount SEK 35.2 million
Capital/Financing Update Classification · 99% confidence The document is a press release announcing the completion of a private placement of convertible instruments (a form of financing/fundraising) totaling SEK 35.2 million, and also mentions the utilization of warrants leading to a share issue. This activity directly relates to the company's capital structure and fundraising efforts. Based on the definitions, the most appropriate category is 'Capital/Financing Update' (CAP). It is not an Annual Report (10-K), an Earnings Release (ER), or a Dividend Notice (DIV). The document is a direct announcement of a financial transaction, not an announcement about the publication of a separate report (RPA).
2018-09-07 English
Oasmia genomför emission av konvertibler om 35,2 miljoner kronor
Capital/Financing Update Classification · 99% confidence The document is titled "PRESSMEDDELANDE" (Press Release) and announces a specific corporate action: the completion of a directed issuance of convertible bonds totaling 35.2 million SEK, along with the issuance of new shares following the exercise of warrants. This clearly relates to fundraising, financing activities, and changes in capital structure. This aligns directly with the definition for Capital/Financing Update (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it details a specific financing event.
2018-09-07 Swedish
Interim / Quarterly Report 2018
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for Oasmia Pharmaceutical AB covering the period May to July 2018. It contains detailed financial statements, including income statements, balance sheet highlights, and management commentary on business operations, product development, and regulatory status. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q2 2018
2018-08-31 Swedish
Interim / Quarterly Report 2018
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report for the period May – July 2018' and contains detailed financial highlights, a CEO review, and business activity updates for the first quarter. It provides actual financial data (net sales, operating loss, net loss, etc.) for the specified period. It meets the criteria for an Interim/Quarterly Report (IR) as it is a comprehensive financial report for a period shorter than a full fiscal year. Q1 2018
2018-08-31 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.